FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:1211-1219 March 18, 2004 Number 12 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Thrombocytosis is typically discovered as an incidental laboratory abnormality when the complete blood count is obtained for some unrelated reason. When found, however, it creates an important diagnostic challenge. Thrombocytosis generally either is a reactive process (secondary thrombocytosis) or is caused by a clonal bone marrow (myeloproliferative) disorder; the latter category includes essential thrombocythemia. It is often exceedingly difficult to differentiate between the reactive and clonal types of thrombocytosis on the basis of clinical findings or laboratory test results. Yet there are fundamental differences between them in terms of cause, pathophysiological features, and clinical implications.

Mechanisms of Thrombocytosis

Thrombopoietin is the key hormone . . . [Full Text of this Article]

Major Causes of Thrombocytosis

Reactive (Secondary) Thrombocytosis

Familial Thrombocytosis

Clonal Thrombocytosis

            Clonality

            Clinical Complications

            Natural History

Differential Diagnosis

Treatment Considerations

Conclusions

Source Information

From the Department of Medicine, University of Pennsylvania School of Medicine and University of Pennsylvania Health System, Philadelphia.

Address reprint requests to Dr. Schafer at the University of Pennyslvania Health System, 100 Centrex, 3400 Spruce St., Philadelphia, PA 19104, or at andrew.schafer@uphs.upenn.edu.

Related Letters:

Thrombocytosis
Cheung M. C., Hicks L. K., Pendergrast J., Schafer A. I.
Extract | Full Text | PDF  
N Engl J Med 2004; 350:2524-2525, Jun 10, 2004. Correspondence

This article has been cited by other articles:

• Vannucchi, A. M., Guglielmelli, P., Tefferi, A. (2009). Advances in Understanding and Management of Myeloproliferative Neoplasms. CA Cancer J Clin 59: 171-191 [Abstract] [Full Text]  
• Lannutti, B. J., Epp, A., Roy, J., Chen, J., Josephson, N. C. (2009). Incomplete restoration of Mpl expression in the mpl-/- mouse produces partial correction of the stem cell-repopulating defect and paradoxical thrombocytosis. Blood 113: 1778-1785 [Abstract] [Full Text]  
• Cazzola, M. (2008). Molecular basis of thrombocytosis. haematol 93: 646-648 [Full Text]  
• Halfdanarson, T. R., Litzow, M. R., Murray, J. A. (2007). Hematologic manifestations of celiac disease. Blood 109: 412-421 [Abstract] [Full Text]  
• Vannucchi, A. M., Barbui, T. (2007). Thrombocytosis and Thrombosis. ASH Education Book 2007: 363-370 [Abstract] [Full Text]  
• Randi, M. L., Putti, M. C., Scapin, M., Pacquola, E., Tucci, F., Micalizzi, C., Zanesco, L., Fabris, F. (2006). Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative. Blood 108: 3600-3602 [Abstract] [Full Text]  
• Nigrovic, L. E., Nigrovic, P. A., Harper, M. B., Chiang, V. W. (2006). Extreme Thrombocytosis Predicts Kawasaki Disease in Infants. CLIN PEDIATR 45: 446-452 [Abstract]  
• Schafer, A. I. (2006). Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 107: 4214-4222 [Abstract] [Full Text]  
• Kondo, S., Tanaka, N., Kubota, S., Mukudai, Y., Yosimichi, G., Sugahara, T., Takigawa, M. (2006). Novel angiogenic inhibitor DN-9693 that inhibits post-transcriptional induction of connective tissue growth factor (CTGF/CCN2) by vascular endothelial growth factor in human endothelial cells. Molecular Cancer Therapeutics 5: 129-137 [Abstract] [Full Text]  
• Tefferi, A., Barbui, T. (2005). bcr/abl-Negative, Classic Myeloproliferative Disorders: Diagnosis and Treatment. Mayo Clin Proc. 80: 1220-1232 [Abstract]  
• Barbui, T., Finazzi, G. (2005). When and How to Treat Essential Thrombocythemia. NEJM 353: 85-86 [Full Text]  
• Mani, H, Luxembourg, B, Klaffling, C, Erbe, M, Lindhoff-Last, E (2005). Use of native or platelet count adjusted platelet rich plasma for platelet aggregation measurements. J. Clin. Pathol. 58: 747-750 [Abstract] [Full Text]  
• Rodwell, G. E. J., Troxell, M. L., Lafayette, R. A. (2005). Renal tubular injury associated with anagrelide use. Nephrol Dial Transplant 20: 988-990 [Full Text]  
• Valade, N., Decailliot, F., Rebufat, Y., Heurtematte, Y., Duvaldestin, P., Stephan, F. (2005). Thrombocytosis after trauma: incidence, aetiology, and clinical significance. Br J Anaesth 94: 18-23 [Abstract] [Full Text]  
• Tenedini, E., Fagioli, M. E., Vianelli, N., Tazzari, P. L., Ricci, F., Tagliafico, E., Ricci, P., Gugliotta, L., Martinelli, G., Tura, S., Baccarani, M., Ferrari, S., Catani, L. (2004). Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells. Blood 104: 3126-3135 [Abstract] [Full Text]  
• Cheung, M. C., Hicks, L. K., Pendergrast, J., Schafer, A. I. (2004). Thrombocytosis. NEJM 350: 2524-2525 [Full Text]